Clinical trials: Diabetes Mellitus Type II,
Diabetic Nephropathies
Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
Diabetic nephropathy (DN) is the commonest cause of chronic kidney disease, and proteinuria isn't determent factor for the end stage renal disease in diabetics.
- Trial name
- NCT04380584
- Testing
- plasma Apelin level
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Type 2 Diabetes Mellitus, Cardiovascular Diseases
The Effect of Potatoes on Markers of Cardiometabolic Health
A 2-period randomized cross-over trial will be conducted to determine the effect of incorporating 1 medium size potato, compared to an isocaloric portion of refined grains, on fasting glucose levels, insulin sensitivity, blood…
- Trial name
- NCT03495284
- Testing
- Potato-based side dish, Refined grain-based
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Penn State University
Diabetes Mellitus
Serum Magnesium Level in Type 2 Diabetes Mellitus
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both .
- Trial name
- NCT06059833
- Testing
- Magnesium
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Sohag University
Aging, Diabetes Mellitus, Type 2
Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management.
- Conditions
- Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity
- Trial name
- NCT05786521
- Testing
- Semaglutide Injectable Product, Lifestyle Counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia and North America. The aim of this trial is to compare two insulin degludec (NN1250, SIBA) formulations with each other and with insulin glargine, all in combination with metformin in…
- Trial name
- NCT00611884
- Testing
- insulin glargine, insulin degludec, metformin
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
Primary Objective: To demonstrate noninferiority of Toujeo versus "standard of care" basal insulin therapy as measured by glycated hemoglobin (HbA1c) change Secondary Objectives: To demonstrate superiority of Toujeo versus…
- Trial name
- REGAIN CONTROL (NCT02967211)
- Testing
- insulin glargine (U300), insulin glargine (U100), NPH insulin
- Where
- 118 sites in Brazil, Finland and 8 more
- Volunteers
- 609 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers
This trial is conducted in the United States of America (USA). The aim of this trial is to compare repaglinide and metformin administered as an individual tablets with repaglinide and metformin administered as a combination…
- Trial name
- NCT01489644
- Testing
- repaglinide, metformin, repaglinide and metformin combination tablet
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Genetics
Phenotyping Genetic Risk for Type 2 Diabetes
This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2…
- Trial name
- NCT04024631
- Testing
- 75g glucose beverage (Glucola, Trutol, or similar brand), DXA, whole body
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
The Long-term Effect of Tianqi Capsule Interventions to Prevent Diabetes in the REDUCES Study: a 8-year Follow-up Study
Objectives: This study is aimed to assess whether Tianqi Capsule interventions have a long-term effect on the risk of diabetes and provide evidence that early intervention by traditional Chinese medicine could delay the…
- Trial name
- NCT02848053
- Testing
- no intervention
- Volunteers
- 420 people
- Sponsor
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Cancer Survivorship, Chemotherapy Side Effects
Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes
The growing U.S. cancer survivor population is projected to hit 26M by 2040. Chemotherapy represents an effective cancer treatment but can diminish cancer survivors' quality of life-particularly cognitive function-through select…
- Trial name
- CICI-PA (NCT06725953)
- Testing
- Social Cognitive Theory-based, Technology-delivered Physical Activity Program
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Oklahoma
Type 2 Diabetes
To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin
The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes on top of insulin.
- Trial name
- NCT00768105
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack
Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on…
- Trial name
- NCT05780905
- Testing
- Semaglutide Auto-Injector
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Diabetes Mellitus, Type 2
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
- Trial name
- NCT04295005
- Testing
- Empagliflozin, DPP-4i, GLP-1-RA
- Where
- Germany
- Volunteers
- 24,500 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
BEYOND represents an open-label, parallel, three-arm randomized controlled trial, aimed at evaluating the effects of combination therapy of fixed ratio basal insulin/GLP-1 receptor agonist (GLP-1RA) or basal insulin/SGLT-2…
- Trial name
- BEYOND (NCT04196231)
- Testing
- IDegLira, IGlarLixi, Insulin/Canaglifozin
- Where
- Italy
- Volunteers
- 258 people
- Sponsor
- University of Campania Luigi Vanvitelli
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST (NCT00442845)
- Testing
- Atorvastatin (Lipitor)
- Where
- 121 sites in Cameroon, Canada and 3 more
- Volunteers
- 2,080 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pediatric Obesity, Type 2 Diabetes
Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study
This is a multicentre, single-arm, feasibility study in adolescents with T2DM and obesity to investigate the recruitment and retention rates to a study using Low Energy Diets(LED).
- Trial name
- LEGEND (NCT06572345)
- Testing
- Low-energy diet, Qualitive interview - LED participants, Qualitive interview - Participants declining LED
- Where
- United Kingdom
- Volunteers
- 73 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Type 2 Diabetes Mellitus
Sotagliflozin Bioequivalence Study
Primary Objective: To determine the bioequivalence of a single dose of the commercial tablet of sotagliflozin (test) compared to the development tablet of sotagliflozin (reference) under fasting conditions in healthy male and…
- Trial name
- NCT03211195
- Testing
- Sotagliflozin (SAR439954)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2, PreDiabetes
Mastering Diabetes Study
This is a program evaluation that will evaluate the effectiveness of Mastering Diabetes, a therapeutic lifestyle change (TLC) program to control prediabetes and type 2 diabetes.
- Trial name
- NCT04454957
- Testing
- Mastering Diabetes
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Ohio University
Diabetes Mellitus, Type 2
The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy
The goal of this clinical trial is to learn if SGLT2 inhibitor Henggliflozin works to improve glucose variability in type 2 diabetes and if Henggliflozin can benefit immunosenescence.
- Trial name
- HOLIDYA (NCT06818851)
- Testing
- Henggliflozin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Type2 Diabetes
Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes
The aim of this single-center, prospective, randomized, double-blind, placebo-controlled, 2-arm parallel-group interventional study is to investigate the effect of 4-week treatment with AP-325 on C-peptide release as measure of…
- Trial name
- NCT05160272
- Testing
- AP-325
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- The Deutsche Diabetes Forschungsgesellschaft e.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.